MIT researchers published a preclinical advance in Nature Nanotechnology showing a novel lipid nanoparticle (LNP) formulation that delivered an influenza mRNA vaccine at roughly 1/100th the dose used with current FDA‑approved materials while generating comparable immune responses in mice. The team screened libraries of degradable cyclic amino ionizable lipids and identified AMG1541 as a top performer for endosomal escape and potent delivery. Authors including Daniel Anderson framed the work as a path to lower cost per dose and reduced reactogenicity for mRNA vaccines. The report highlights rational ionizable‑lipid design and biodegradability as levers to improve potency and safety profiles for the next generation of mRNA therapeutics.